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https://doi.org/10.1016/j.neuron.2018.09.044SUMMARY
Through the generation of humanized FUS mice
expressing full-length human FUS, we identify that
when expressed at near endogenous murine FUS
levels, both wild-type and ALS-causing and fronto-
temporal dementia (FTD)-causing mutations com-
plement the essential function(s) of murine FUS.
Replacement of murine FUS with mutant, but not
wild-type, human FUS causes stress-mediated in-
duction of chaperones, decreased expression of
ion channels and transporters essential for synaptic
function, and reduced synaptic activity without loss
of nuclear FUS or its cytoplasmic aggregation.
Most strikingly, accumulation of mutant human FUS
is shown to activate an integrated stress response
and to inhibit local, intra-axonal protein synthesis in
hippocampal neurons and sciatic nerves. Collec-
tively, our evidence demonstrates that human ALS/
FTD-linked mutations in FUS induce a gain of
toxicity that includes stress-mediated suppression
in intra-axonal translation, synaptic dysfunction,
and progressive age-dependent motor and cognitive
disease without cytoplasmic aggregation, altered
nuclear localization, or aberrant splicing of FUS-
bound pre-mRNAs.816 Neuron 100, 816–830, November 21, 2018 ª 2018 The Author(s)
This is an open access article under the CC BY license (http://creativeINTRODUCTIONAmyotrophic Lateral Sclerosis (ALS) is a neurodegenerative dis-
order leading to paralysis from death of motor neurons. Muta-
tions in the gene encoding the RNA binding protein FUS (fused
in sarcoma) are causative of cases of familial ALS (Kwiatkowski
et al., 2009; Vance et al., 2009) as well as instances of frontotem-
poral dementia (FTD) (Broustal et al., 2010; Van Langenhove
et al., 2010; Yan et al., 2010). FUS is present in the pathological
inclusions of patients with FUS-mediated ALS and most of FTD
instances without TDP-43 or Tau-containing aggregates, ac-
counting for about 10%of the frontotemporal lobar degeneration
(FTLD) cases, known as FTLD-FUS (Mackenzie et al., 2010).
FUS-containing aggregates have been reported in both the nu-
cleus and the cytoplasm of neurons and glial cells in the central
nervous system (CNS) of patientswithFUSmutationsor sporadic
disease (Belzil et al., 2011; Chio et al., 2011; DeJesus-Hernandez
et al., 2010; Kim et al., 2014b; Rademakers et al., 2010; Vance
et al., 2009) as well as neurodegenerative conditions including
Huntington’s disease (Doi et al., 2008). The relocalization of
FUS from thenucleus to thecytoplasm is incomplete,with at least
some nuclear retention in neurons with FUS inclusions (Munoz
et al., 2009; Neumann et al., 2009; Rademakers et al., 2010).
The 526-amino-acid FUS protein includes a glycine-rich, low-
complexity, prion-like domain and a C-terminal, non-classical
PY nuclear localization signal (PY-NLS) in which most of the
ALS/FTLD-linked mutations are clustered (Da Cruz and Cleve-
land, 2011). Like TDP-43, inmost cell types FUS ismainly nuclear. Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
(Andersson et al., 2008). Beyond nuclei, FUShasbeen reported in
neurons to be enriched in dendrites (Belly et al., 2005; Yasuda
et al., 2013), spines (Fujii et al., 2005), in close proximity of presyn-
aptic vesicles (Schoen et al., 2016), and at the neuromuscular
junctions (So et al., 2018). Reduction (Udagawa et al., 2015) or
deletion (Hicks et al., 2000) of Fus inmouse hippocampal neurons
causes abnormal spine morphology and density, consistent with
a role for FUS in modulation of neuronal plasticity or synaptic ac-
tivity—potentially through the alteration of mRNA stability (Uda-
gawaet al., 2015) or transport and local translation in neurons (Fu-
jii et al., 2005).While some studies have reported that a proportion
of wild-type FUS is recruited to cytoplasmic stress granules,
others have found that only FUS mutants localize to stress gran-
ules (Aulas and Vande Velde, 2015).
FUShasbeen proposed to participate in a range of cellular pro-
cesses including transcription, splicing, RNA localization and
degradation, and DNA damage (Lagier-Tourenne et al., 2010).
Genome-wide analyses have reported that FUS binds between
5,000 and 8,000 mammalian RNA targets (reviewed in Nuss-
bacher et al., 2015) and that deletion of the gene is associated
with alterations in levels and splicing of 1,000 mRNAs (Honda
etal., 2013; Ichiyanagiet al., 2016;Kapeli et al., 2016; Lagier-Tour-
enneet al., 2012).Nevertheless, deletionofFus fromoutbredmice
(Kuroda et al., 2000) or from inbredmaturemousemotor neurons
does not cause their degeneration (Sharma et al., 2016). Efforts to
model FUS-mediated disease in rodents have used heterologous
promoters (that do not fully recapitulate the pattern of expression
of endogenous FUS) to drive, inmost cases, elevated levels of hu-
manwild-type (Mitchell et al., 2013; So et al., 2018) ormutant FUS
(Huang et al., 2011; Qiu et al., 2014; Sephton et al., 2014; Sharma
et al., 2016; Shelkovnikova et al., 2013; Shiihashi et al., 2016;
Verbeeck et al., 2012). Others have used heterozygous or homo-
zygous removal of the nuclear localization domain of mouse Fus
(Devoy et al., 2017; Scekic-Zahirovic et al., 2017; Scekic-Zahir-
ovic et al., 2016). Both sets of efforts have suggested that gain
of toxicity is a component of pathogenesis. However, the identi-
ty(ies) of possible acquired toxicities remains unknown, and
whether loss of function contributes to disease is not established.
We have now generated humanized FUSmice in which the full-
length human FUS gene, encoding wild-type or ALS-linked muta-
tions, replaces murine Fus. With expression levels close to the
normal levels of endogenous FUS, wild-type or mutant FUS
mimics the predominantly nuclear localization of endogenous
FUS and complements its essential function(s). Mutant FUS is
shown tocauseprogressivemotor andcognitive deficits—without
detectablecytoplasmicaggregation—accompaniedbyRNAalter-
ations inexpression that are drivenbyagain-of-toxicity rather than
a loss of FUS function. Most strikingly, mutant FUS is shown to
inhibit local intra-axonal protein translation, drive synaptic loss,
elevate stress-induced chaperones, and suppress RNAs encod-
ing ion channels and transporters essential for synaptic function.
RESULTS
Mice with Human FUS Expression Mimicking
Murine FUS
Transgenic mice were generated in a C57BL/6 congenic back-
ground to express wild-type (WT) FUS or either of twoALS-linked mutations (R521C and R521H), each transcribed
from the endogenous human FUS promoter (Figure 1A).
Twenty-six founder mice were obtained expressing human FUS
WT (hgFUSWT), R521C (hgFUSR521C), or R521H (hgFUSR521H)
(Figure S1A). Eight lines were established (Figure S1B).
Accumulated human FUS levels were comparable in most
lines using an antibody recognizing both human and mouse
FUS proteins with equivalent affinity (Figures 1B, S1D, and
S1E). Endogenous FUS was reduced by more than 50% at
mRNA (Figures 1C and S1C) and protein (Figures 1B and 1D)
levels, resulting in overall FUS protein levels similar to endoge-
nous mouse FUS levels in non-transgenic (Non-Tg) animals (Fig-
ure 1B). Lines with matching levels (line 88 for WT, line 10 for
R521C, and line 9 for R521H; Figures 1C and 1D) and expression
pattern of human FUS (determined in spinal cord sections
stained with an antibody specifically recognizing human, but
not mouse, FUS) mimicking that of the endogenous mouse
FUS (Figure 1E) were further characterized.
Age-Dependent Motor Deficits Without Nuclear FUS
Mislocalization or Cytoplasmic Aggregation in ALS/
FTD-Linked Mutant FUS Mice
Motor performance of all three FUS (hgFUSWT, hgFUSR521C, and
hgFUSR521H) mouse lines at 2 months of age was undistinguish-
able from that of Non-Tg littermates. By 8 months, both mutant
FUS lines had developed significant reduction in hindlimb grip
strength compared to age-matched Non-Tg and hgFUSWT litter-
mates (Figure 2A). Motor dysfunction in both mutant lines was
further exacerbated during aging, reaching a loss of grip strength
of over 50% by 18 months. Loss of motor performance was
accompanied by age-dependent loss of muscle innervation (Fig-
ures 2B and 2C), a-motor axons (Figures 2D–2F), and spinal cord
motor neurons (Figures 2G and 2H). There was also a modest
decline in the number of innervated neuromuscular junctions
(NMJs) (Figure 2C) and a-motor axons in age-matched hgFUSWT
mice relative to Non-Tg animals (Figures 2E and 2F).
Loss of motor neurons in mutant animals was accompanied
by increased activation of astrocytes (Figures S2A and S2C)
and microglia (Figures S2B and S2C) in spinal cord ventral
horns of hgFUSR521C and hgFUSR521H mice (scored by GFAP
and Iba1 immunoreactivity, respectively). FUS protein levels
remained unchanged up to 24 months of age across all geno-
types (Figures 2I and 2J). Similarly, although elevated expres-
sion of mutant FUSR521C driven by a prion promoter has been
proposed to cause accumulation of DNA damage in mouse spi-
nal cords (Qiu et al., 2014), no such damage (measured by
gH2A.X and 53BP1 co-localization) was observable in aged,
diseased hgFUSR521C and hgFUSR521H mice (Figure S2D),
although it was obvious in the spinal cords of g-irradiated
animals.
Age-dependent motor deficits in ALS-causing mutant
FUS lines were not accompanied by cytoplasmic redistribution
of either human (Figures 2K and S2E) or mouse (Figures 2L
and S2E) FUS or FUS aggregates (Figures 2K–2L and S2F)
in 24-month-old spinal cords. Taken together, neither FUS
aggregates nor redistribution to the cytoplasm are necessary
for age-dependent motor deficits in the hgFUSR521C and
hgFUSR521H lines.Neuron 100, 816–830, November 21, 2018 817
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Figure 1. Expression Levels and Cellular Pattern
of the Human FUS Transgene Mimics That of
Endogenous Protein with an Auto-regulation
Mechanism
(A) Schematic of the human BAC containing human FUS
gene wild-type (WT) or either ALS-linked mutation
R521C or R521H.
(B) Protein levels of the 54 and 53kDa human andmouse
FUS using an antibody recognizing both species with
equal affinity. Calnexin was used as a loading control.
Each lane represents an independent mouse spinal
cord.
(C) Expression levels of total (mouse, blue bars and
human, red bars) FUS RNAs in Non-Tg, hgFUSWT,
hgFUSR521C, and hgFUSR521H spinal cords. Data are
represented as mean ± SEM (n = 3 per group). See also
Figure S1.
(D) Protein levels of the human FUS transgene using an
antibody specific to the human protein and mouse FUS
using an antibody specifically recognizing the mouse
protein in 2-month-old animals (* non-specific band).
Each lane represents an independent mouse spinal
cord per transgenic line. Calnexin was used as a loading
control.
(E) Lumbar spinal cord sections from 2-month-old Non-
Tg, hgFUSWT, hgFUSR521C, and hgFUSR521H mice
immunostained for human FUS transgene (green) and
total FUS (red). Scale bars, 200 and 50 mm.ALS/FTD-LinkedMutations in FUSDriveAge-Dependent
Cognitive Deficits and Synaptic Loss
Age-dependent deficits in cognition and memory were devel-
oped in hgFUSR521C and hgFUSR521H mice, including novel
object recognition (Figure 3A), spatial memory (Figure S3A), so-
ciability (Figures S3B and S3C) and anxiety (Figure S3D). These
alterations were accompanied by modest increases in astroglio-
sis (Figures 3B and 3C) and microgliosis (Figures 3B and 3D), as
well as a significant loss of synapses (marked by loss of synap-
sin; Figures 3E and 3F) in the hippocampus of aged, 24-month-
old mice, without loss of NeuN positive neurons. Mutant-
FUS-dependent loss of synapsin was recapitulated in cultured
primary hippocampal neurons (Figure 3G). Neuronal activity818 Neuron 100, 816–830, November 21, 2018measurements (using multi-electrode arrays
[MEA]; Chailangkarn et al., 2016) revealed
age- and mutant-dependent synaptic
dysfunction, with a 50% decrease in spike
rate developing by 28 days of culture (Figures
3H and 3I).Progressive Neurodegeneration in
Humanized Mutant FUS Mice
We next generated humanized FUS mice
(mFus//hgFUS mice) in which the sole
source of FUS was human FUS. This was
achieved by mating to produce mice that ex-
pressed our wild-type or mutant human
FUS-encoding transgenes but in which both
endogenous Fus alleles were inactivated (Fig-
ure 4A). While homozygous disruption ofmurine Fus is lethal in C57BL/6 mice, as previously reported
(Hicks et al., 2000), lethality was completely rescued by expres-
sion of human wild-type or mutant FUS, and humanized FUS
mice (eitherWT ormutants) were bornwith the expectedMende-
lian ratios (Figures 4B and 4C). Nevertheless, despite compara-
ble humanFUSmRNA (FigureS4A) andprotein levels (Figure 4C),
beginning at 6 months of age, hgFUSR521C or hgFUSR521H mice
developed progressive motor deficits including age-dependent
loss of hindlimb grip strength (Figure 4D) and loss of spinal
cord ChAT-positive motor neurons (Figure S4B). Remarkably,
reduction or elimination of endogenous Fus did not exacerbate
mutant FUS-dependentmotor deficits and neurotoxicity (Figures
2 and 4).
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Figure 2. ALS-Linked FUS Mutants Show Age-Dependent Progressive Motor Impairments without Nuclear Mislocalization or Aggregation
of FUS
(A) Hindlimb grip strength measured up to 24 months. Data are represented as mean ± SEM (n R 12 per group). *p < 0.05, **p < 0.01, ***p < 0.001, ns: non-
significant using one-way ANOVA.
(B) Gastrocnemius muscle sections from 24-month-old Non-Tg, hgFUSWT, hgFUSR521C, and hgFUSR521Hmice with axons immunostained using a synaptophysin
antibody and FluoroMyelin red (red) and muscle endplates using a-bungarotoxin (green). Scale bar, 50 mm.
(C) NMJ innervation of the gastrocnemius from 8- and 24-month-old Non-Tg, hgFUSWT, hgFUSR521C, and hgFUSR521H mice. Data are represented as mean ±
SEM (nR 3 mice per group). *p < 0.05, ***p < 0.001, two-sided unpaired Student’s t test.
(D) Lumbar motor axons from 24-month-old Non-Tg, hgFUSWT, hgFUSR521C, and hgFUSR521H mice. Scale bar, 50 mm.
(E) Size distribution per motor axon in the L5motor root of 24-month-old Non-Tg, hgFUSWT, hgFUSR521C, and hgFUSR521Hmice. Data are represented asmean ±
SEM (nR 3 per group). *p < 0.05, **p < 0.01 and ***p < 0.001, two-sided unpaired Student’s t test.
(legend continued on next page)
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ALS/FTD-Mediated DiseaseWithout Loss of Normal FUS
Function
To determine whether age-dependent loss of FUS nuclear func-
tion contributes to FUS-mediated disease in aged, humanized
FUSmice, levels (Figure 4E) and splicing (Figure 4F) of the genes
most affected by FUS depletion in mice (Lagier-Tourenne et al.,
2012) were assessed. Expression levels of Kcnip4, Park2,
Smyd3, Mal, Nrxn3, Nlgn1, and Csmd1 were significantly
decreased in the CNS of mice treated with reduced FUS
following antisense oligonucleotide-mediated degradation of
Fus mRNAs (Figure 4E; Lagier-Tourenne et al., 2012). However,
a modest increase, rather than a reduction, was seen in the
expression of these genes in spinal cords of humanized
hgFUSR521C and hgFUSR521H mice compared to Non-Tg and
hgFUSWT mice depleted of endogenous FUS (Figure 4E).
Genome-wide expression analysis (RNA-seq; Figure S4C) of
aged, humanized mutant FUS spinal cords did not significantly
overlap with the changes identified upon FUS depletion in adult
mouse spinal cords (Kapeli et al., 2016) (Figure S4E). Similarly,
the most common splicing changes identified upon depletion
of FUS (Lagier-Tourenne et al., 2012) were not observed in the
humanized FUS mouse spinal cords (Figure 4F). Global splicing
analysis using the RNA-mediated oligonucleotide annealing, se-
lection, and ligation with next-generation sequencing (RASL-
seq) method (which permitted quantitative profiling of 3,859
alternative splicing events that correspond to exon inclusion or
skipping events conserved between mouse and human;
Scekic-Zahirovic et al., 2016; Sun et al., 2015; Zhou et al.,
2012) did not reveal significant splicing alterations in aged, hu-
manized mutant FUS spinal cords (Figure S4D). Altogether,
these results demonstrate that the age-dependentmotor deficits
associated with expression of ALS-linked FUSmutant in human-
ized FUS mice cannot be caused by a loss of function of FUS in
regulating gene expression and/or splicing.
A Mutant FUS-Dependent Gain of Toxicity RNA
Signature Affecting Protein Synthesis
RNA expression profiles from spinal cords of humanized mutant
FUS mice were used to test whether ALS-linked mutations pro-
duced expression changes that reflected gain of aberrant func-
tion (Figures 5 and S4E). RNA profiles from normal (Non-Tg)
and humanized hgFUSWT mice were almost indistinguishable.
However, both humanized mutant FUS lines had highly distinct
RNA profiles determined with unsupervised hierarchical clus-
tering (Figure 5A) and principal component analysis (PCA) (Fig-
ure 5B), with 1,057 significant expression changes (defined by(F) Total number of a-motor axons (caliber size > 4.5 mm) in the L5motor root of 8- a
are represented as mean ± SEM (nR 3 per group).
(G) Lumbar spinal cord sections from 24-month-old Non-Tg, hgFUSWT, hgFUSR
cholinergic motor neurons. Scale bar, 100 mm.
(H) Total number of ChAT-positive motor neurons in lumbar spinal cords of 8- and
represented as mean ± SEM (nR 3 per group). *p < 0.05, **p < 0.01, two-sided
(I) Total human and/or mouse FUS protein levels in spinal cords of 2-, 12-, and 24-
used as a loading control. Asterisk illustrates a non-specific band recognized by
(J) Quantification of immunoblots shown in (I). Data are represented as mean ± S
(K and L) Lumbar spinal cord sections from 24-month-old Non-Tg, hgFUSWT, hgF
specifically (K) human or (L) mouse FUS. DNA is stained with DAPI. Scale bars, 1
820 Neuron 100, 816–830, November 21, 2018p < 0.05 adjusted for multiple testing; Table S1) and with 709
down and 348 upregulated genes (Figure 5C) relative to age-
matched Non-Tg or humanized hgFUSWT littermates. These
changes (Figures 5D and 5E) included altered signaling path-
ways for protein translation mediated by eIF2a, a crucial transla-
tion initiation factor which forms a complex with components
including eIF2B, GTP, and the initiating methionine tRNA (Kapur
et al., 2017). mTOR and glutamate receptor signaling pathways
(Figure 5E) were also affected.
mRNAs encoding multiple ion channels and transporters
essential for synaptic function were decreased in spinal cord ex-
tracts of both humanized mutant FUS lines (Figure S5A), consis-
tent with mutant FUS-dependent synaptic dysfunction (Figures
3E and 3F). Further tests using RT-qPCR confirmed reductions
in ion channel and transporter components tested (reductions
in nine are shown in Figure 5F). These changes were accompa-
nied by the upregulation of ten genes encoding chaperones (Fig-
ure S5B), five of which were further validated by qRT-PCR (Fig-
ure 5G). Genes encoding ribosomal proteins represented some
of themost downregulated genes, including sixteen components
of the translation machinery (Figures 5H and S5C).
Stress-Mediated Inhibition of Intra-axonal Protein
Synthesis from ALS/FTD-Linked Mutations in FUS
FUS mutant-dependent effects on protein translation mediated
through eIF2a were tested in the nervous system of the human-
ized FUS mice. Phosphorylation of eIF2a on serine 51 inhibits
overall initiation by blocking the activity of its eIF2B guanine ex-
change factor (Donnelly et al., 2013). Consistent with inhibited
translation initiation, elevated levels of phosphorylated eIF2a
(P-eIF2a), together with increased levels of HSF1 (heat shock
transcription factor 1), were identified in spinal cord protein
extracts from FUS adult mutant mice at early symptom onset
(Figure 6A, S6A, and S6B).
ATF4 is a key effector of the integrated stress response that
drives phosphorylation of eIF2a (Pakos-Zebrucka et al., 2016).
Consistent with P-eIF2a dependent protein synthesis inhibition,
there was a mutant FUS-dependent increase of Atf4 mRNA
levels in primary mouse hippocampal neurons (Figure 6B).
Correspondingly, mRNA translation was reduced (compared
with neurons of wild-type mice) by 25% in metabolically labeled
(with 35S-Met/Cys) cultured hippocampal neurons from mutant
FUS mice (Figure 6C).
Recognizing that puromycin incorporation into nascent poly-
peptides enables direct visualization of actively translating ribo-
somes (using an anti-puromycin antibody; tom Dieck et al.,nd 24-month-old Non-Tg, hgFUSWT, hgFUSR521C, and hgFUSR521Hmice. Data
521C, and hgFUSR521H mice immunostained using a ChAT antibody to reveal
24-month-old Non-Tg, hgFUSWT, hgFUSR521C, and hgFUSR521Hmice. Data are
unpaired Student’s t test.
month-old hgFUSWT, hgFUSR521C, hgFUSR521H, and Non-Tg mice. Tubulin was
the antibody against mouse FUS.
EM from two independent experiments.
USR521C, and hgFUSR521H mice immunostained using an antibody recognizing
00 mm and 50 mm (inset). See also Figure S2.
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Figure 3. Age-Dependent Progressive Cognitive Impairments, Astrogliosis, and Microgliosis in Hippocampus of Mice Expressing ALS-
Linked FUS Mutants
(A) Novel object recognitionwasmeasured in 12- and 24-month old Non-Tg, hgFUSWT, hgFUSR521C, and hgFUSR521Hmice. Data are represented asmean ± SEM
(n = 15 per group). *p < 0.05 using one-way ANOVA. See also Figure S3.
(B) Quantification of the GFAP and Iba1 relative fluorescence intensities in hippocampal sections of 24-month-old Non-Tg, hgFUSWT, hgFUSR521C, and
hgFUSR521H mice. The bar graph represents mean ± SEM (n = 3 per group). *p < 0.05, **p < 0.01, two-sided unpaired Student’s t test.
(CandD)Hippocampal sections from24-month-oldNon-Tg, hgFUSWT, hgFUSR521C, andhgFUSR521Hmice immunostainedusinganantibodydetectingactivated (C)
astrocytes (GFAP) or (D) microglia (Iba1). DNA is stained with DAPI. Scale bar, 50 mm.
(E) Hippocampus from 24-month-old Non-Tg, hgFUSWT, hgFUSR521C, and hgFUSR521H mice immunostained to reveal synapses (green) using a synapsin
antibody and DAPI for nuclei. Scale bar, 25 mm.
(F) Quantification of the synapsin relative fluorescence intensity shown in (E). The bar graph represents mean ± SEM (n = 3 per group). *p < 0.05, two-sided
unpaired Student’s t test.
(G) Synapsin and FUS protein levels in hippocampal neuronal extracts frommutant hgFUSR521H or Non-Tgmice (at 15 days of culture). Tubulin antibody was used
as loading control.
(legend continued on next page)
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2015), we cultured hippocampal neurons in compartmented mi-
crofluidic chambers that allow unambiguously distinguishing cell
bodies from processes, prior puromycin pulse-labeling (Figures
6D and 6E). Surprisingly, translation was found to be predomi-
nantly reduced in processes (Figures 6E, 6G, 6I, and 6K) relative
to cell bodies (Figures 6F, 6H, 6J, S6C, and S6D). This reduction
was accompanied by increased phosphorylation of eIF2a in
axons (Figures 6G and 6M), with no differences observed in
cell bodies (Figures 6F and 6L). No cell death was detected at
any time point (Figures S6E and S6F).
While a majority of FUS localized intranuclearly (Figure 6H,
red), both wild-type and mutant human FUS were present in
axons of hippocampal neurons cultured in compartmented
microfluidic chambers (Figure 6I). FUS was not elevated in the
cytoplasm of mutant neuronal cell bodies (Figures 6H and 6N).
However, relative to wild-type FUS, significantly more mutant
FUS accumulated within axons (Figures 6I and 6O). Since mea-
surement of the volume covered by the axonal network in our
hippocampal neuronal cultures revealed that it was at least
6 times that of their cell bodies and dendrites, this strong reduc-
tion in intra-axonal protein translation is likely to be sufficient to
account for the 25% decreased protein synthesis measured in
the total protein extract (Figure 6C).
To test mutant FUS effects on local translation in motor
axons in mice, puromycin pulse labeling of sciatic nerve axons
was achieved by its systemic administration into the mice, as
previously reported (Goodman et al., 2011; Khoutorsky et al.,
2015; Figure 7A). Increased phosphorylation of eIF2a (green
signal by immunofluorescence) was observed in sciatic nerve
axons (neurofilament positive; red) in both hgFUSR521C and
hgFUSR521H mice at early symptom onset, but not in age-
matched Non-Tg or hgFUSWT animals (Figures 7B and 7E).
Consistent with our findings in the hippocampal neurons (Figures
6E–6O and S6C–S6D), intra-axonal protein synthesis (revealed
by decreased puromycin signal) was almost eliminated (Figures
7C–7D and 7F), along with increased accumulation of ALS-
linked mutants of FUS (Figures 7D and 7G) within sciatic nerve
axons of the two mutant FUS lines, but not their Non-Tg and
hgFUSWT littermates. Taken together, our in vitro and in vivo
evidence demonstrates that ALS-linked mutations of FUS impair
local protein synthesis within axons.
DISCUSSION
A key question regarding pathogenic mechanisms in FUS-medi-
ated disease has been whether ALS-linked mutations in FUS
cause neurodegeneration through a loss and/or gain of toxicity.
By producing and analyzing humanized FUS mice in which wild-
type or ALS-causing mutations in human FUS replace endoge-
nous murine Fus, we demonstrate that both human wild-type
and ALS/FTD-linked FUS mutants complement the essential
functions of murine FUS. When expressed at a level and subcel-(H) Spontaneous neuronal spike rate (spikes per s) measured by multi-electrode
Non-Tg mice cultured under basal conditions. Data are represented as mean ±
periments). ***p < 0.001, two-sided unpaired Student’s t test.
(I) Raster plots fromMEA recordings showing neuronal spikes and burst of spikes
represents spikes per s recorded per electrode.
822 Neuron 100, 816–830, November 21, 2018lular distribution that mimic endogenous FUS, mutant human
FUS provokes progressive motor and cognitive deficits in mice
that are accompanied by RNA alterations driven by a gain of
toxicity rather than a loss of function of FUS, but without detect-
able cytoplasmic aggregation.
While high levels of wild-type FUS cause early lethality in mice
(Mitchell et al., 2013; Sephton et al., 2014), our mice expressing
wild-type FUS at levels close to the normal level of murine FUS
also developed motor deficits during aging. When taken with a
report that ALS patients with mutations in the 30 UTR region of
FUS accumulate those variants at increased levels in patient fi-
broblasts (Sabatelli et al., 2013), it is therefore likely that even a
modest increase in FUS (humanmutant or wild-type) is sufficient
to trigger age-dependent motor deficits.
To an earlier report that FUS depletion from iPSC-derived
motor neurons produces a different RNA signature than a dis-
ease-linked FUS mutation (Kapeli et al., 2016), our analyses
have identified that the overwhelming majority of gene expres-
sion alterations associated with age-dependent motor and
cognitive deficits in humanized mutant FUS mice do not over-
lap with those altered upon depletion of FUS (Kapeli et al.,
2016; Lagier-Tourenne et al., 2012). Depletion of FUS in the
adult mouse CNS leads to more than 300 splicing changes
(Kapeli et al., 2016; Lagier-Tourenne et al., 2012) and disrupts
non-canonical, U12-dependent splicing of RNAs (Reber et al.,
2016) in a neuronal cell line. While cytoplasmic aggregates of
an ALS-linked FUS mutant were reported to inhibit U12-medi-
ated splicing of a subset of introns by trapping of snRNAs in
aggregates (Reber et al., 2016), and ALS-linked mutant-
dependent splicing changes have previously been reported
in patient fibroblasts (Sun et al., 2015) as well as in motor
neuron precursor cells derived from iPSCs (Ichiyanagi et al.,
2016), no significant splicing changes in the nervous system
of humanized mutant FUS mice were identified despite initia-
tion of adult-onset disease. The major splicing alterations
identified upon in vivo FUS depletion (Lagier-Tourenne et al.,
2012) were not recapitulated in diseased, mutant humanized
FUS mice. Thus, FUS-mediated neurodegeneration in mice
cannot be caused primarily by reduced FUS activity, a
conclusion fully consistent with the finding that deletion of
FUS from mature motor neurons does not provoke disease
(Sharma et al., 2016).
Several mechanisms underlying FUS-mediated toxicity have
now been proposed, including aggregation and redistribution
of mutant FUS into the cytoplasm (Dormann et al., 2012; Mack-
enzie et al., 2011; March et al., 2016). Morphology and distribu-
tion of FUS inclusions vary among the CNS of different neuro-
degenerative conditions, with FUS inclusions reportedly being
nuclear in Huntington’s disease (Doi et al., 2008) but primarily
cytoplasmic in ALS and FTLD (King et al., 2015; Mackenzie
et al., 2011), with some nuclear retention in even the most
affected neurons with FUS inclusions (Munoz et al., 2009;arrays (MEA) in hippocampal neurons from mutant hgFUSR521H compared to
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Figure 4. Progressive Motor Deficits Associated with ALS-Linked FUS Mutants Without Reduction in FUS Function
(A) Schematic of the two-round mating of hgFUSmice with FUSmice heterozygous for mouse FUS (mFus+/) to produce animals in which all FUS is human wild-
type or mutant (mFus//hgFUS).
(B) Number and Mendelian ratio of animals obtained from the two-step mating.
(C) Human and mouse FUS protein accumulation in 2-month old mouse spinal cords using FUS antibodies specific for human and mouse proteins. GAPDH was
used as a loading control. Asterisk illustrates a non-specific band detected with the mouse-specific FUS antibody.
(D) Hindlimb grip strength measured bi-weekly from 2 to 18 months of age. Data are represented as mean ± SEM (nR 15 per group). *p < 0.05, **p < 0.01 and
***p < 0.001 using one-way ANOVA.
(legend continued on next page)
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Figure 5. ALS-Linked Mutations in FUS Cause aMutant-Dependent Signature of RNAs that Includes a Reduction in mRNAs for Ion Channels
and Transporters and Ribosomal Proteins and an Increase in mRNAs Encoding Chaperones
(A) Unsupervised hierarchical clustering of all expressed genes in spinal cords of 18-month-old Non-Tg, mFus//hgFUSWT, mFus//hgFUSR521C, and
mFus//hgFUSR521H mice identified by RNA-seq analysis.
(B) Principal component analysis (PCA) of differentially expressed genes in 18-month-old Non-Tg, mFus//hgFUSWT, mFus//hgFUSR521C, and
mFus//hgFUSR521H spinal cords.
(C) Heatmap with hierarchical clustering of 1,057 genes differentially expressed in 18-month-old hgFUSR521C and hgFUSR521H mice compared to age-matched
Non-Tg and mFus//hgFUSWT spinal cords.
(D) Functional analysis using DAVID software of the differentially expressed genes revealing the most enriched gene group changes in mFus//hgFUSR521C and
mFus//hgFUSR521H mice compared to age-matched Non-Tg and mFus//hgFUSWT animals.
(E) Functional analysis using the Ingenuity Pathway Analysis (IPA) software of the differentially expressed genes revealing the most enriched gene group changes
in mFus//hgFUSR521C and mFus//hgFUSR521H mice compared to age-matched Non-Tg and mFus//hgFUSWT animals.
(F) Reduced expression of ion channels and transporters essential for synaptic function in 18-month-old mFus//hgFUSR521C and mFus//hgFUSR521H spinal
cords compared to age-matched Non-Tg and mFus//hgFUSWT, validated by qRT-PCR. Data are represented as mean ± SEM (nR 3 per group). *p < 0.05,
**p < 0.01, two-sided unpaired Student’s t test. See also Figure S5A.
(G) Increased expression of chaperones in 18-month-old mFus//hgFUSR521C and mFus//hgFUSR521H spinal cords compared to age-matched Non-Tg and
mFus//hgFUSWT, validated by qRT-PCR. Data are represented as mean ± SEM (nR 3 per group). *p < 0.05, **p < 0.01 and **p < 0.001, two-sided unpaired
Student’s t test. See also Figure S5B.
(H) Reduced expression of genes encoding ribosomes or other components of the translation machinery in 18-month-old mFus//hgFUSR521C and
mFus//hgFUSR521H spinal cords compared to age-matched Non-Tg and mFus//hgFUSWT, validated by qRT-PCR. Data are represented as mean ± SEM
(nR 3 per group). *p < 0.05 and **p < 0.01, two-sided unpaired Student’s t test. See also Figure S5C.Neumann et al., 2009; Rademakers et al., 2010). To these pre-
ceding efforts, we report that age-dependent motor and cogni-
tive deficits develop in humanized mutant FUS mice without(E) Expression levels of candidate genes (known to be reduced in the CNS ofmice
figure 3I) in 18-month-old Non-Tg, mFus//hgFUSWT, mFus//hgFUSR521C, an
SEM (nR 3 per group). *p < 0.05, **p < 0.01, two-sided unpaired Student’s t tes
(F) Splicing profile of candidate genes (known to be altered in the CNS of mice de
18-month-old Non-Tg, mFus//hgFUSWT, mFus//hgFUSR521C, and mFus//h
824 Neuron 100, 816–830, November 21, 2018detectable human FUS cytoplasmic aggregation. Thus, while
we cannot rule out FUS aggregates in the cytoplasm in forms
undetectable by our analyses, large aggregates similar todepleted of FUS [light gray], previously reported in Lagier-Tourenne et al., 2012;
d mFus//hgFUSR521H mouse spinal cords. Data are represented as mean ±
t.
pleted of FUS, previously reported in Lagier-Tourenne et al., 2012; figure 4C) in
gFUSR521H mouse spinal cords. See also Figure S4.
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Figure 6. ALS-Linked Mutations in FUS Cause Stress-Mediated Reduction in Axonal Protein Synthesis
(A) Immunoblot demonstrating increased stress mediated bymutant FUS at early symptom onset using the phosphorylated form of eIF2a antibody (P-eIF2a) and
HSF1 antibody in 12-month-old hgFUSR521C and hgFUSR521H spinal cords compared to age-matched Non-Tg and hgFUSWT. eIF2a and tubulin antibodies were
used as loading controls. See also quantification in Figures S6A and S6B.
(B) Expression of Atf4 in primary hippocampal neuronal cultures from hgFUSR521H compared to Non-Tg mice. Data are represented as mean ± SEM (n R 3
biological replicates per group). *p < 0.05, two-sided unpaired Student’s t test.
(C) Quantification of the amount of 35S incorporated into newly translated proteins in hippocampal neurons cultured for 15 days. Cycloheximide (25 mg/mL)
addition was used as a positive control for complete protein translation inhibition. Data are represented as mean ± SEM (n = 4 biological repeats). **p < 0.01,
two-sided unpaired Student’s t test.
(D) Schematic of the experimental design using microfluidic compartmented chambers to distinguish neuronal cell bodies from axons.
(E–G) Hippocampal neurons isolated from hgFUSR521H or Non-Tg mice (from four independent experiments with 3 or 4 mouse embryos per genotype per
experiment) cultured in compartmented chambers and treated with a 10-min pulse of puromycin to label protein translation sites using puromycin antibody
(green) with a neurofilament NF-H (white) antibody to stain axons (E) or with an antibody recognizing the phosphorylated form of eIF2a (P-eIF2a) (red) in (F) cell
bodies and (G) neuronal processes. Scale bars, 10 mm and 50 mm, respectively.
(H and I) Hippocampal neurons isolated from hgFUSR521H and hgFUSWTmice cultured in compartmented chambers immunostained for FUS (using FUS antibody
in red) and protein translation (using puromycin antibody in green) in (H) cell bodies and (I) axonal processes (using NF-H antibody, white). Scale bar, 50 mm.
(J–M) Quantification of the puromycin relative fluorescence intensity (protein translation) in (J) cell bodies (green signal in Figure 6F) and (K) axons (green signal in
Figure 6G); quantification of P-eiF2a fluorescence intensity (stress) in (L) cell bodies (red signal in Figure 6F) and (M) axons (red signal in Figure 6G) of Non-Tg and
hgFUSR521H hippocampal neurons cultured in microfluidic chambers. The bar graph represents mean ± SEM (nR 30 axons or cell bodies per group from four
independent experiments). ***p < 0.001, two-sided unpaired Student’s t test.
(N and O) Quantification of FUS relative fluorescence intensity in (N) cell bodies (red signal in Figure 6H) and (O) axons (red signal in Figure 6I). The bar graph
represents mean ± SEM (nR 50 axons or cell bodies per group). ***p < 0.001, two-sided unpaired Student’s t test.those seen at end-stage disease in patients are not required
for disease initiation, consistent with several other neurode-
generative diseases in which large inclusions correlate poorly
with either onset or severity of neurodegeneration (Arnoldet al., 2013; Arrasate et al., 2004; Kirkitadze et al., 2002;
Parone et al., 2013).
Increasing evidence suggests that RNA-binding proteins
including TDP-43, FMRP, SMN, and ataxin-2 are involved inNeuron 100, 816–830, November 21, 2018 825
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Figure 7. ALS-Linked Mutations in FUS Cause Stress-Mediated Reduction in Local Axonal Protein Synthesis within Sciatic Nerve Axons of
Mutant FUS Mice
(A) Experimental design to assess stress and local axonal translation in the sciatic nerve of 12-month-old Non-Tg, hgFUSWT, hgFUSR521C, and hgFUSR521H mice.
(B) Transversal sections of mouse sciatic nerves immunostained using P-eIF2a (green) and NF-H (red) antibodies and (C) puromycin (green) antibody.
(D) Longitudinal sections of mouse sciatic nerves immunostained using puromycin (green), NF-H (red), and FUS (blue) antibodies. Scale bars, 10 mm.
(E–G) Quantification of the relative fluorescence intensity of the (E) P-eIF2a, (F) puromycin, and (G) FUS immunostainings within sciatic nerve axons of 12-month-
old Non-Tg, hgFUSWT, hgFUSR521C, and hgFUSR521H mice. The bar graph represents mean ± SEM (n = 3 animals per group). ***p < 0.001, two-sided unpaired
Student’s t test.the regulation of local protein translation and that local transla-
tion is critical for synaptic function (Donlin-Asp et al., 2017).
FUS is present not only in soma but also along neuronal den-
drites in RNA granules (Belly et al., 2005; Yasuda et al., 2013),
spines (Fujii et al., 2005) in close proximity to presynaptic vesi-
cles (Schoen et al., 2016), and at the neuromuscular junctions
(So et al., 2018). To this, we now demonstrate that FUS protein
is present along axons, including at sites of intra-axonal protein
synthesis, and that the accumulation of ALS-linked mutants
of FUS is significantly increased along axons and dendrites of
hippocampal and sciatic nerve neurons.
FUS has been proposed to play a role at the synapse in spine
formation (Fujii et al., 2005) and maturation (Udagawa et al.,
2015) of hippocampal neurons, possibly by regulating local
mRNA translation of synaptic components such as GluA1 (Uda-
gawa et al., 2015) or RNAs enriched in cell protrusions (Yasuda
et al., 2017; Yasuda et al., 2013). A role as a RNA chaperone
suppressing RNA folding and repeat-associated translation of
UGGAA expanded repeats has also been described in a fly826 Neuron 100, 816–830, November 21, 2018model for ataxia (Ishiguro et al., 2017). While expression of
high levels of FUS mutants was reported to provoke a reduc-
tion in protein synthesis in neuronal cultures (Murakami et al.,
2015) and alter dendritic branching and spines in mice (Seph-
ton et al., 2014), it is not established whether—and, if so,
how—mutations in FUS may alter such critical functions. In
flies, synaptic transmission at the neuromuscular junctions of
Drosophila larvae expressing FUS mutants was significantly
decreased (Shahidullah et al., 2013). Our efforts provide in vivo
evidence in the mammalian nervous system that expression of
FUS mutants at levels approximating the normal level of endog-
enous FUS is sufficient to cause stress-mediated reduction in
intra-axonal protein synthesis prior to synaptic dysfunction
and loss and is therefore likely to contribute to synaptic
dysfunction associated with age-dependent motor and cogni-
tive deficits.
Indeed, we have demonstrated FUS mutant-dependent sup-
pression of expression of a wide range of components of the
protein translation machinery, including mRNAs from the large
and small ribosomal subunits. Correspondingly, FUS may play
a role in the translation of a wide range of genes. This contrasts
with other RNA-binding proteins whose actions have recently
been proposed to exert translational control on a specific sub-
set of genes (examples include ataxin 2 on RGS8 [Dansithong
et al., 2015], FMRP on diacylglycerol kinase kappa [Tabet
et al., 2016], or FMRP together with TDP-43 on Rac1,
Map1b, and GluR1 [Majumder et al., 2016]). Future efforts are
now needed to identify the spectrum of axonal RNAs affected
by FUS mutations. Added to this, mutations in FUS impair
axonal transport, including transport of mitochondria and endo-
plasmic reticulum vesicles in patient-derived (Guo et al., 2017)
and Drosophila (Baldwin et al., 2016) motor neurons. It is there-
fore possible that alterations in axonal transport of RNAs
contribute to the reduction in local intra-axonal protein
synthesis.
Finally, we find an early activation of the integrated stress
response (ISR) pathway with increased phosphorylation of
eIF2a (Pakos-Zebrucka et al., 2016; Zhao and Ackerman,
2006). Thus, we propose that ALS-linked mutations in FUS
lead to increased accumulation of mutant FUS along axons,
including at local intra-axonal translation sites; this in turn pro-
vokes local ISR that inhibits local protein synthesis, ultimately
impairing neuronal synaptic function. Chemical ISR inhibitors
have been reported to increase long-term memory (Sidrauski
et al., 2013), reverse cognitive deficits associated with trau-
matic brain injury (Chou et al., 2017) in rodents and reduce
TDP-43 mediated toxicity in flies and neuronal cultures (Kim
et al., 2014a). It will now be of high interest to test whether
modulating ISR pathways using similar compounds reduces
the age-dependent motor and cognitive deficits associated
with mutant FUS.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Generation of hgFUS BAC transgenic mice
The human BAC construct expressing the full length FUS gene (18.2Kb) was obtained using DNA recombineering from the RP11-
157F22 BAC clone. The sequences of the 50 and 30 homology arms used to retrieve the human FUS gene were: CCCCATAGCTGGG
CAAATTTAGGCCAACACTC and CTAAGCGTGGTGGCGGGCGCCTGTAG. The ALS-linked mutations (R521C and R521H) were
introduced using site-specific mutagenesis. Each construct was flanked by LoxP sites to further allow Cre-mediated excision of
the human FUS gene in cell of interest. No other gene is on the BAC. The modified constructs (FUS wild-type or harboring either
the R521H or R521Cmutation) was injected into the pronuclei of fertilized C57BL/6 eggs and implanted into pseudo-pregnant female
mice. All themice used in this report weremaintained on a pure C57BL/6 background. All experimental procedures were approved by
the Institutional Animal Care and Use Committee of the University of California, San Diego.
Primary cultures
Primary hippocampal neuron cultures
Primary hippocampal neurons were prepared from embryonic day 16-17 (E16-E17). Hippocampal tissues were treated with 0.25%of
Trysin+EDTA for 15 min at 37C. Trypsin activity was inhibited using DMEM:F12 media supplemented with 10% of FBS and 1% of
Penicillin/Streptomycin and tissues were then mechanically disaggregated using 1000 mL tips. A 4% BSA (in PBS1x) solution was
further added to the cell suspension and centrifuged for 10 min at 1000rpm. The cell pellet was resuspended in Neurobasal media
supplemented with 2% of B27, 200mM of L-glutamine and 100U/mL of penicillin-streptomycin. Cells were seeded in culture plates
previously coated with poly-D-lysine at the concentration of 600,000 cells/mL.e2 Neuron 100, 816–830.e1–e7, November 21, 2018
METHOD DETAILS
Immunofluorescence
Mice were perfused intracardially and fixed with 4% paraformaldehyde in 0.1 M Sorenson’s phosphate buffer, pH 7.2, the entire
spinal cord was dissected, post-fixed for 2 hours in the same fixative and transferred in a 30% sucrose phosphate buffer for at least
2 days. The lumbar spinal cord or brain was embedded in OCT compound (Sakura) and snap frozen in isopentane (2-methylbutane)
cooled at 40C on dry ice. Floating lumbar spinal cord or brain cryosections (30mm or 35mm, respectively) were incubated in a
blocking solution containing PBS1x, 0.5% Tween-20, 1.5% BSA for 1.5 hours at room temperature and then in PBS1x, 0.3% Triton
X-100 overnight at room temperature with the primary antibodies (listed in antibodies section). Primary antibodies were washed with
PBS1x and then detected using donkey anti-rabbit or anti-mouse FITC or Cy3 (1:500) coupled secondary antibodies (Jackson
ImmunoResearch). The sections were washed with PBS1x and mounted. Analysis was performed on a Nikon Eclipse laser scanning
confocal microscope. Fluorescence intensity from unsaturated images captured with identical confocal settings (minimum of four
spinal sections were imaged per animal) was quantified using NIS elements software (Nikon).
Morphometric Analysis of Axons
Mice were perfused intracardially and fixed with 4% paraformaldehyde in 0.1 M Sorenson’s phosphate buffer, pH 7.2, and the L5
lumbar roots were dissected and conserved in the same fixative at 4C. L5 roots were embedded in Epon-Araldite as described
in the electron microscopy section, thick sections (0.75mm) were prepared and stained for light microscopy with toluidine blue. Cross
sections of L5motor axons were analyzed at each age group. Axonal diameters weremeasured using the Bioquant Software and the
number of large caliber axons with diameters over 4.5mm (a motor axons) was determined.
Motor neuron counting
ChAT positive ventral horn motor neurons were counted from 25-35 lumbar spinal cord cryosections (per animal) spaced 360mm
apart and expressed as the average of total motor neurons counted divided by the number of sections.
Neuromuscular junction innervation
Gastrocnemius muscle was dissected from perfused mice and prepared as described in the immunofluorescence section. Floating
40 mm thick longitudinal sections of gastrocnemius were incubated in a blocking solution containing PBS1x, 0.5% Tween-20, 1.5%
BSA for 4 hours at room temperature and then in PBS1x, 0.3% Triton X-100 overnight at room temperature with the polyclonal rabbit
anti-synaptophysin antibody at 1:50 (Invitrogen). The sections were washed with PBS1x and then incubated first with donkey anti-
rabbit Cy3 (Jackson ImmunoResearch) and a-bungarotoxin-Alexa488 (Invitrogen) at 1:500 for 1 hour at room temperature and then
with Fluoromyelin red (Invitrogen) at 1:300 for 30 min. The sections were further washed with PBS1x and mounted. Analysis was
performed on a Nikon Eclipse laser scanning confocal microscope. A total of approximately 1,000 neuromuscular junctions were
counted from at least 10 sections of gastrocnemius. Individual NMJs were considered as innervated when synaptophysin staining
covered at least 50% of the area of a-bungarotoxin staining.
In vivo protein synthesis labeling
Intraperitoneal injection of puromycin (10mg/kg) was performed in 12-month-old mice. Exactly 30 min post-injection (Goodman
et al., 2011; Khoutorsky et al., 2015), mice were deeply anesthetized and perfused and fixed with 4% paraformaldehyde in 0.1 M
Sorenson’s phosphate buffer, pH 7.2. Sciatic nerves were dissected and post-fixed for 3 hours at 4C, transferred in a 30% sucrose
phosphate buffer and crypreserved. 30 mm thick longitudinal and transversal sections of sciatic nerves were processed for immuno-
fluorescence, as described above.
Immunoblotting
Spinal cords fromNon-Tg or hgFUSmice were homogenized in cold PBS1x supplemented with protease inhibitors. The lysates were
centrifuged for 10 min at 1,000 x g and the resulting supernatants (clarified tissue extract) were analyzed by immunoblotting. Equal
protein amounts were separated on SDS-PAGE, transferred to nitrocellulose membranes and probed with the indicated antibodies
followed by horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch). Pico or Femto ECL (Pierce) was
used to detect immunoreactive bands.
Antibodies
Rabbit anti-phosphorylated eIF2a (Ser51) (1:100; Cell Signaling; #9721S); Rabbit anti-eiF2a (1:1000; Cell Signaling; #9722S); Mouse
anti-FUS (4H11) (1:1000; Santa Cruz, sc-47711); Rabbit anti-FUS (1:500; Bethyl, A300-302A); Goat anti-FUS (1:500; Bethyl, A303-
839A); Rabbit anti-FUS (1:500; Proteintech 11570-1-AP); Mouse anti-GAPDH (6C5) (1:10,000; Abcam, ab8245); Mouse anti-GFAP
(clone G-A-5) (1:500; Millipore, MAB360); Rabbit anti-HSF1 (1:100; Cell Signaling, 4356S); Rabbit anti-Hsp90 (C45G5) (1:1000;
Cell Signaling, 4877S); Rabbit anti-Iba1 (1:500; Wako, 019-19741); Chicken anti-Map2 (1:500; Novus Biological; NB300-213); Mouse
anti-Neurofilament Clone RT97 (1:500; Millipore, MAB5262); Rabbit anti-neurofilament H (1:500; Millipore, ab1989); Mouse anti-
Neurofilament H non-phosphorylated SMI-32 (1:500; Covance, SMI32R); Mouse anti-Nucleophosmin (1:1000; Zymed, 32-5200);Neuron 100, 816–830.e1–e7, November 21, 2018 e3
Chicken Neurofilament H (1:1000, Millipore, AB5539); Chicken anti-NeuN (1:1,000, Millipore, ABN91); Mouse anti-puromycin (1:100;
Millipore, MABE343); Conjugated Alexa 488 anti-puromycin (1:100; Millipore, MABE343-AF488); Rabbit anti-synapsin-1 (1:500 IF;
1:1000WB; SYSY synaptic systems, 106103); Mouse anti-gH2A.X (1:5000; Millipore 05-636); Rabbit anti-53BP1 (1:5000; Novus Bio-
logical NB100-304); Rabbit anti-calnexin (1:1,000; Enzo, SPA-860); Mouse anti-tubulin (DM1A clone) (1:10,000, home-made); Rabbit
anti-human FUS #14080 (1:25000; home-made) and anti-mouse FUS #14082 (1:4000, home-made).
Nuclear-Cytosolic Fractionation
Spinal cords were dissected, weighed, and fresh tissue was gently lysed in 10x (vol/wt) hypotonic buffer A (10 mM HEPES-KOH
pH 7.4, 10 mM KCl, 1.5 mM MgCl, 0.5 mM EDTA, 0.5 mM EGTA), 1x protease inhibitors (Roche) using a pre-chilled glass dounce
homogenizer (tight fit). After 15 min on ice, 2.5 M sucrose [0.5x (vol/wt)] was added and samples were centrifuged at 800 x g for
5 min. The supernatant was collected as the cytosolic fraction, and the nuclear pellet was washed with buffer A. Following centrifu-
gation, the nuclear pellet was resuspended in 5x (vol/wt) buffer B [10 mM HEPES-KOH pH 7.4, 0.42 M NaCl, 2.5% (vol/vol) glycerol,
1.5 mM MgCl, 0.5 mM EDTA, 0.5 mM EGTA, 1 mM DTT, 1x protease inhibitors], and incubated at 4C while rotating at 60 rpm for
1 hour. Both the nuclear and cytosolic fractions were then centrifuged at 16,100 x g for 10 min at 4 C.
Sequential Biochemical Fractionation
Spinal cords from mice were dissected, weighed, and homogenized in 4 mL/g of high-salt buffer (HS buffer: 50 mM Tris pH 7.5,
750 mM NaCl, 5 mM EDTA, and protease inhibitor mixture), and then centrifuged at 45,000 x g for 30 min at 4 C. The pellets
were extracted with HS containing 1% (wt/vol) Triton X-100 (TX fractions). Pellets were homogenized in 500 mL of HS buffer contain-
ing 1% (wt/vol) Triton X-100 and 1M sucrose, and upon centrifugation, floatingmyelin was removed. Pellets were then extracted with
2 mL/g of urea buffer (7 M urea, 2 M thiourea, 4% (wt/vol) CHAPS, 30 mM Tris pH 8.5), followed by 2 mL/g of SDS loading buffer.
Equivalent volumes of samples were separated on 10% Bis-Tris gels for immunoblotting with the indicated antibodies.
Total-body mouse g-irradiation
To obtain a positive control for DNA damage accumulation in mouse spinal cords, Non-Tg mice (n = 3) were irradiated for 10 min
at 10Gy of g-rays. Animals were perfused within 2 hours after irradiation and processed for immunofluorescence staining using
anti-gH2A.X and 53BP1 antibodies as previously described (Ahmed et al., 2017; Koch et al., 2016).
Cell viability assay
The viability of the neurons was tested using LIVE/DEAD Reduced Biohazard Viability/Cytotoxicity Kit (Molecular Probes). Neurons
grown in 96 well plates were incubated with the kit solution mix for 15 min in complete darkness at room temperature. The cells were
then rinsed with HBSS and fixed with freshly prepared 4% of glutaraldehyde for 15 min at room temperature before imaging by
confocal microscopy.
Multi-electrode array (MEA)
Each well of a 12-well MEA plate from Axion Biosystems was coated with poly-D-lysine prior to cell seeding. Hippocampal neurons
from Non-Tg and hgFUSR521H mice embryos were plated at the same density (40,000 neurons per well), with duplicate wells for each
embryo. Cells were fed every 3-4 days andmeasurements were taken before themediumwas changed. Recordings were performed
using aMaestroMEA system and AxIS software (Axion Biosystems), using a band-pass filter with 0.1 Hz and 5 kHz frequency cutoffs.
Spike detection was performed using the neural Spikes analog setting (1200XGain, 200-5000Hz) and an adaptive threshold set to
5.5 times the standard deviation of the estimated noise on each electrode. Each plate first rested for 5 min in the Maestro, and
then 5min of data were recorded to calculate the spike rate per well. MEA analysis was performed using the Axion BiosystemsNeural
Metrics Tool, wherein electrodes that detected at least 5 spikes/minute were classified as active electrodes. Bursts were identified in
the data recorded from each individual electrode using an adaptive threshold algorithm. Network bursts were identified for each well
requiring a minimum of ten spikes with a maximum inter-spike of 100 ms. Only channels that exhibited bursting activity (more than
10 spikes in 5-min interval) were included in the analysis.
Compartmentalized microfluidic devices
Themicrofluidic devices were prepared as previously described (Niederst et al., 2015). Master molds were fabricated by photolithog-
raphy, by the Bioengineer Department of the University of California, San Diego, Nano3 Cleanroom Facility. Devices were molded by
soft lithography using Sylgard 182 (Ellsworth Adhesives, Germantown, WI) as previously described (Taylor et al., 2005). After cured,
the cut devices where bath-sonicated in water, washed in 70% ethanol and dried under the hood before mounted onto glass cov-
erslips. The devices were coated with 1X poly-D-lysine 2 hours at 37C and washed sequentially in water and PBS1x before plating
the cells.
Puromycin incorporation assay
Primary hippocampal neurons after 5 or 15 days of culture were incubated for 10 min with puromycin at 1mg/mL. After the incubation
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(1:100) for 1 hour at room temperature. Fluorescence was visualized using an Olympus confocal microscope and images were
acquired using a 60X objective.
[35S]-Methionine Labeling/Radioactivity assay
Primary hippocampal neurons were cultivated for 15 days. Medium in each well was exchanged to Met-/Cys- medium for 25 min
before being supplemented with 1mCi/mL [35S]-Met media (for a final dosage of 0.1mCi/mL). [S35]-Met media containing
25mg/mL cycloheximide was used as negative control for radioactivity incorporation. After 2 hours of incubation with [35S]-Met at
0.1mCi/mL, incorporation was stopped with cycloheximide (25mg/mL) and cells collected immediately in ice-cold PBS1X. Cells
were lysed with RIPA buffer (50mM Tris pH8.0, 50mM NaCl, 5mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS)
containing proteinase inhibitors and total cellular protein was co-precipitated with 100mg of BSA carrier protein using trichloroacetic
acid. Samples were acetone washed, resuspended in 2% SDS-PBS1X, and transferred into scintillation fluid. Counts per minute
(Cpms) averaged over 5-min windows were measured with a Beckman LS6000 SC scintillation counter (normalized to scintillation
fluid only). Cpms were then normalized to total well protein concentration determined by densitometry from a silver-stained gel.
RNA extraction and qPCR
To isolate total RNA from cells or tissues, TRIzol (Invitrogen) and treatment with RQ1DNase I (Promega) was used. Reverse transcrip-
tionwas performed using the SuperScript First Strand Kit (Invitrogen) according tomanufacturer’s instructions. qPCRwas performed
on 40ng of cDNA using the iQSYBR Green Supermix (Bio-Rad) with the iCycler iQ detection system according to manufacturer’s
instructions. Analysis was performed using the iQ5 optical system software (Bio-Rad; version 2.1). Expression values were ex-
pressed as a percentage of the average expression of control samples. All reactions were carried out in duplicate in three indepen-
dentmice (per genotype) and actin B or cyclophilin and/or rsp9 genes were alsomeasured as standard genes across all experimental
conditions. To enable determining human FUS RNA levels compared to mouse Fus, primer sequences common to both human and
mouse were used to measure total FUS RNAs. In parallel, primer sequences specific to mouse Fus were designed to measure
uniquely mouse Fus RNAs. Human FUS (compared to endogenous) is then obtained by subtracting mouse Fus from total FUS levels.
Real-time quantitative RT-PCR (RT/qPCR) was performed to determine mRNA levels in spinal cord or hippocampal neurons from
transgenic mice (see primer sequence in Table S2).
RNA-seq
Total RNA from spinal cords of 18-month-old mFus//hgFUS (WT, R521C or R521H) and their Non-Tg control littermates were ex-
tracted with TRIzol (Invitrogen). RNA quality was measured using the Agilent Bioanalyzer system according to the manufacturer’s
recommendations and processed using the Illumina TruSeq Stranded mRNA Sample Preparation Kit according to manufacturer’s
protocol. A total of 14 cDNA libraries were simultaneously generated and sequenced using an Illumina HiSeq 2000 sequence, as pre-
viously described (Scekic-Zahirovic et al., 2016), before fastq files were obtained from Illumina demultiplexing ‘‘bcl2fastq’’. Then
fastq files were aligned to a mouse reference genome (mm9, UCSC Genome Browser) using TopHat (Trapnell et al., 2009) and
the transcript abundance for each annotated protein-coding gene as fragments per kilobase of transcript per million mapped reads
(FPKM) were estimated by Cufflinks (Trapnell et al., 2010). Sequencing yielded, on average, 15million non-redundant reads per sam-
ple. 13,468 genes, which expressed FPKM > = 1 were kept for downstream analyses. The spearman correlation among samples as
well as Principle Component Analysis (PCA) was applied to those 12,922 genes (expressing consistently within the same category).
The proportion of variance for dimension 1 (PC1) and dimension 2 (PC2) shown in Figure 5B was of 0.9 and 0.1, respectively. Cuffdiff
(Trapnell et al., 2013), a part of the Cufflinks package, was used to detect the differentially expressed genes (DEGs). Unsupervised
hierarchical clustering with complete method was applied on the heatmap showing DEGs between wild-type and mutant samples.
Gene ontology of those DEGswas estimated by David and Ingenuity Pathway Analysis (IPA). All sequencing raw data were submitted
to Gene Expression Omnibus (GEO) with accession number GSE120247.
RASL-seq
RASL-seq analysis of splicing switches was carried out as detailed (Scekic-Zahirovic et al., 2016; Sun et al., 2015; Zhou et al., 2012).
A pool of oligonucleotides was designed to detect 5,859 alternative splicing events. One hundred fmol of RASL-seq oligos were
annealed to 1 mg of total RNA isolated from mouse spinal cords. After ligation, 5 ml eluted ligated oligos was used for 1620 cycles
of PCR amplification, and the bar-coded PCR products were sequenced on HiSeq2000 with 24-30 samples in one lane. Sequencing
data were decoded allowing no mismatch with each barcode, and target sequences were mapped with RASL-seq oligo pool
sequences. Ratios of the counts of shorter to longer isoforms were calculated.
Splicing gels
Semiquantitative qRT-PCR (25-30 cycles) was used to assess splicing changes most affected upon FUS depletion identified by
(Lagier-Tourenne et al., 2012). Isoform productswere separated on 10%polyacrylamide gels and stainedwith SYBRgold (Invitrogen)
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Mouse behavioral tests
Grip strength
Grip strength was measured using a Grip Strength Meter (Columbus Instruments, Columbus, OH) on cohorts (nR 15) made up of
approximately the same number of males and females. Mice were allowed to grip a triangular bar only with hind limbs, followed by
pulling the mice until they released; five force measurements were recorded in each separate trial.
Y maze test
Spontaneous alternation behavior, a measure of spatial working memory, exploratory behavior, and responsiveness to novelty (La-
londe, 2002), was tested using a Y maze with 34 3 8 3 14-cm arms. Each mouse was tested in a single 5-min trial in which arm
choices and total numbers of arm entries were recorded. Spontaneous alternation, expressed as a percent, refers to the ratio of
sets of three unique arm choices (i.e., visiting arm 3 then 1 then 2 in sequence) to the total number of arm entries. Because mice
have the opportunity to do repeated entries into a single arm, there is a chance performance level of 22% (2/9) for spontaneous
alternations (Holcomb et al., 1999; Pennanen et al., 2006). In our hands, healthy young C57BL6/J mice typically make 50%–70%
spontaneous alternations in this test. A cohort of n = 15 animals (per genotype) was assessed.
Social interaction test
This test was originally developed to model in mice aspects of autism spectrum disorders in humans (Moy et al., 2004; Moy et al.,
2007) and has been usedwidely by behavioral neuroscientists (Silverman et al., 2010). Individuals on the autism spectrum show aber-
rant reciprocal social interaction, including low levels of social approach and unusual modes of interaction. The social interaction
apparatus is a rectangular, three chambered Plexiglas box, with each chamber measuring 20 cm x 40.5 cm x 22 cm (L x W x H).
Dividing walls are clear with small semicircular openings (3.5 cm radius) allowing access into each chamber. The middle
chamber is empty, and the two outer chambers contain small, round wire cages (Galaxy Cup, Spectrum Diversified Designs, Inc.,
Streetsboro, OH) during testing. The mice were habituated to the entire apparatus with the round wire cages removed for 5 min.
To assess sociability, mice were returned to the middle chamber, this time with a stranger mouse (B6 of the same sex being tested,
habituated to the wire cage) in one of the wire cages in an outer compartment and another identical wire cage in the opposite
compartment. Time spent in the chamber with the stranger mouse and time spent in the chamber with the novel object was recorded
for 5 min. For the social novelty preference test, mice were returned to the middle chamber, this time with the original mouse (familiar
mouse) in its chamber and a new unfamiliar mouse (novel mouse) in the previously empty wire cage. Again, time spent in each cham-
ber was recorded for 5 min. Youngmale B6mice spendmore time with the novel mouse in the sociability test (Moy et al., 2004), how-
ever we have found less preference for the novel mouse as compared to the now familiar mouse in the social novelty preference test
(Jackson et al., 2015). A cohort of n = 15 animals (per genotype) was assessed.
Novel object recognition test
This test assays recognition memory while leaving the spatial location of the objects intact and is believed to involve the hippocam-
pus, perirhinal cortex, and raphe nuclei (Lieben et al., 2006; Mumby et al., 2005; Winters et al., 2004). The basic principal is that an-
imals explore novel environments and that with repeated exposure decreased exploration ensues (i.e., habituation). A subsequent
object substitution (replacing a familiar object with a novel object) results in dishabituation of the previously habituated exploratory
behavior (Ennaceur and Delacour, 1988). The resulting dishabituation is expressed as a preferential exploration of the novel object
relative to familiar features in the environment. This dishabituation has generally been interpreted as an expression of the animal’s
recognition memory: the novel object is explored preferentially because it differs from what the animal remembers (Heyser and
Chemero, 2012) and requires attention by the animals. Mice were individually habituated to a 51cm x 51cm x 39cm open field for
5 min and then tested with two identical objects placed in the field (either two 250 mL amber bottles or two clear plastic cylinders
6x6x16cm half filled with glass marbles). Eachmouse was allowed to explore the objects for 5 min. After three such trials (each sepa-
rated by 1 min in a holding cage), the mouse was tested in the object novelty recognition test in which a novel object replaced one of
the familiar objects (for example, an amber bottle if the cylinders were initially used). All objects and the arena were thoroughly
cleaned with 70% ethanol between trials to remove odors. Behavior was video recorded and then scored for contacts (touching
with nose or nose pointing at object andwithin 0.5 cmof object). Habituation to the objects across the familiarization trials (decreased
contacts) is an initial measure of learning and then renewed interest (increased contacts) in the new object indicated successful ob-
ject memory. Recognition indexes were calculated using the following formula: # contacts during test/(# contacts in last familiariza-
tion trial + # contacts during test). Values greater than 0.5 indicate increased interest, whereas values less than 0.5 indicate
decreased interest in the object during the test relative to the final familiarization trial. A cohort of n = 15 animals (per genotype)
was assessed.
Cued and contextual fear conditioning
In this procedure, mice learn to associate a novel environment (context) and previously neutral stimuli (conditioned stimuli, a tone and
light) with an aversive foot shock stimulus (Maren, 2001). It allows for the assessment of both hippocampus-dependent and amyg-
dala-dependent learning processes in the same mouse (Kenney and Gould, 2008; Rudy et al., 2004). Testing then occurs in the
absence of the aversive stimulus. Conditioned animals, when exposed to the conditioned stimuli, tend to refrain from all but respi-
ratory movements by freezing. Freezing responses can be triggered by exposure to either the context in which the shock was
received (context test) or the conditioned stimulus (CS+ test). Conditioning took place in Freeze Monitor chambers (Med Associates,
Inc.) housed in sound proofed boxes. The conditioning chambers (263 263 17 cm) were made of Plexiglas with speakers and lights
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On day 1, mice were placed in the conditioning chamber for five minutes in order to habituate them to the apparatus. On day 2, the
mice were exposed to the context and conditioned stimulus (30 s, 3000 Hz, 80 dB sound + white light) in association with foot shock
(0.60 mA, 2 s, scrambled current). Specifically, the mice received 3 shock exposures in their 6 min test, each in the last 2 s of a 30 s
tone/light exposure. On day 3, contextual conditioning (as determined by freezing behavior) was measured in a 5-min test in the
chamber where the mice were trained (context test). On the following day, the mice were tested for cued conditioning (CS+ test).
The mice were placed in a novel context for 3 min, after which they were exposed to the conditioned stimuli (light + tone) for
3 min. For this test, the chamber was disguised with new walls (white opaque plastic creating a circular compartment in contrast
to a clear plastic square compartment) and a new floor (white opaque plastic in contrast to metal grid). Freezing behavior (i.e., the
absence of all voluntary movements except breathing) was measured in all of the sessions by real-time digital video recordings cali-
brated to distinguish between subtle movements, such as whisker twitches, tail flicks, and freezing behavior. Freezing behavior in the
context and cued tests (relative to the same context prior to shock and an altered context prior to tone, respectively) is indicative of
the formation of an association between the particular stimulus (either the environment or the tone) and the shock; i.e., that learning
had occurred. A cohort of n = 15 animals (per genotype) was assessed.
QUANTIFICATION AND STATISTICAL ANALYSIS
The number of independent repeats (n), the statistical test used for comparison and the statistical significance (p values) are specified
for each figure panel in the representative figure legend. Data are presented as mean ± SEM. Data were analyzed and graphs were
generated using GraphPad Analysis software.
DATA AND SOFTWARE AVAILABILITY
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